<DOC>
	<DOCNO>NCT02775591</DOCNO>
	<brief_summary>The purpose study determine whether DA-9701 ( Motilitone ) effective safe treatment health-related quality life Parkinson 's disease ( PD ) patient gastrointestinal symptom .</brief_summary>
	<brief_title>Effect Short-term Motilitone Therapy Health-related Quality Life PD Patients With Gastrointestinal Symptoms</brief_title>
	<detailed_description>Gastrointestinal ( GI ) symptoms frequently complain PD patient . To improve symptom , prokinetics often use clinic . However , prokinetics dopamine receptor antagonist aggravate motor symptom PD patient develop tardive dyskinesia affect dopamine receptor brain . DA-9701 ( Motilitone ) recently develop herbal medication 5-HT4 agonism D2 antagonism . Furthermore , cross blood brain barrier safely use PD patient . Hypothetically potential good choice treatment GI symptom PD patient . However , study evaluate efficacy safety randomize clinical trial PD patient . This study evaluate efficacy safety DA-9701 double-blind placebo-controlled phase 1 ( 4 week ) , long-term safety DA-9701 open-label phase 2 ( 8 week phase 1 ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<criteria>Subjects enrol voluntarily understood content clinical trial . Male female Parkinson disease ( PD ) patient 50 80 year Subjects receive prokinetics ( itopride , mosapride , Corydalis tuber , levosulpiride , domperidone , etc . ) least 2 month prior baseline visit Subjects complain least one symptom follow suggests abnormal bowel function : anorexia , nausea , abdominal distension , dyspepsia , early satiety , dysphagia , foreign body sensation associate meal , symptom gastroesophageal reflux , constipation , defecation problem . History gastrointestinal operation Subjects active gastrointestinal disease treatment gastroenterology within 1 month Existence clinically significant cognitive decline KMinimental Status Exam score 20 less Subjects depression psychiatric disorder treat medication antidepressant antipsychotic ; mood tranquilizer , benzodiazepine , sleep pill permit fix dose period clinical trial Subjects severe active comorbidities could interfere quality life patient Subjects medical condition make difficult enrol trial judge clinician Subjects hypersensitivity adverse event relate DA9701 ( Motilitone ) Prior participation clinical trial within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>